Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today

Simply Wall St.07-30

Viking Therapeutics has delivered a very large 5 year return for shareholders, yet at around US$33.86 per share today the stock still screens as expensive on Simply Wall St's valuation checks. Recent ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655081536?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-30 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655081536","market":"sg","top_or_hot":-1,"title":"Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today","media":"Simply Wall St.","content":"<div>\n<p>Viking Therapeutics has delivered a very large 5 year return for shareholders, yet at around US$33.86 per share today the stock still screens as expensive on Simply Wall St's valuation checks. Recent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-above-fair-value-today\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics (VKTX) Stock Looks Above Fair Value Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-30 03:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-above-fair-value-today><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics has delivered a very large 5 year return for shareholders, yet at around US$33.86 per share today the stock still screens as expensive on Simply Wall St's valuation checks. Recent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-above-fair-value-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"THNR","symbol_name":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-above-fair-value-today","article_id":"2655081536","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-vktx-stock-looks-above-fair-value-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655081536","pubTimestamp":1785352569,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Viking Therapeutics has delivered a very large 5 year return for shareholders, yet at around US$33.86 per share today the stock still screens as expensive on Simply Wall St's valuation checks. Recent share price weakness adds another layer, with the broader valuation score not pointing to an obvious bargain despite the long term gains.\n\nViking Therapeutics has returned about 467% over 5 years, which puts extra focus on whether the current price already reflects a lot of optimism.\nExcitement...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","TACU":"T. Rowe Price Active Core U.S. Equity ETF","TSPA":"T. Rowe Price U.S. Equity Research ETF","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","CDIG":"City Different Investments Global Equity ETF","VKTX":"Viking Therapeutics, Inc.","BK4139":"生物科技","BK4599":"减肥药"},"translate_title":"Viking Therapeutics (VKTX) 股票今天看起来高于公允价值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDIG":0.81,"THNR":0.6,"VKTX":1.5,"OZEM":0.6,"TACU":0.81,"TSPA":0.81},"content_text":"Viking Therapeutics has delivered a very large 5 year return for shareholders, yet at around US$33.86 per share today the stock still screens as expensive on Simply Wall St's valuation checks. Recent share price weakness adds another layer, with the broader valuation score not pointing to an obvious bargain despite the long term gains.  Viking Therapeutics has returned about 467% over 5 years, which puts extra focus on whether the current price already reflects a lot of optimism. Excitement around new diabetes and metabolic treatments can support high expectations for Viking Therapeutics, while execution risk and future funding needs may weigh on how much investors are prepared to pay. The company passes 0 of 6 valuation checks on Simply Wall St, which means the stock leans expensive rather than reading as a clear bargain on the broader metrics 0/6.  The issue now is whether Viking Therapeutics' strong long term return history justifies paying what the current valuation metrics are implying. Find out why Viking Therapeutics' 2.9% return over the last year is lagging behind its peers. AdvertisementHas Viking Therapeutics Run Too Far on Book Value? P/B can be a useful cross check for Viking Therapeutics because the company is still loss making and does not have a meaningful P/E yet. On this measure, Viking Therapeutics trades at about 7.8x book value. That is above both the biotech industry average of roughly 2.4x and the peer group average of about 6.3x. The gap indicates investors are paying a premium to the sector for the company’s asset base, even before considering any future revenue traction. Despite the recent interest in new diabetes and metabolic therapies across the sector, this premium leaves the stock screening as expensive on a simple balance sheet yardstick. The valuation model also heavily weights the current losses, which underscores that the shares are priced above what many biotech companies command on book value alone. On the P/B multiple, Viking Therapeutics currently screens as more expensive relative to both its industry and closer peers. NasdaqCM:VKTX P/B Ratio as at Jul 2026 See what the numbers say about this price — find out in our valuation breakdown. The Viking Therapeutics Narrative: What Would Justify Today's Price? Simply Wall St Narratives for Viking Therapeutics pick up where the valuation checks leave off and focus on what would need to happen with Viking Therapeutics' growth, margins and future earnings for the stock to be worth materially more or less than today’s price. Instead of a single output from a ratio or model, Narratives describe the future that number depends on so you can follow how events line up with it over time on the Community page. One of the top community narratives on Viking Therapeutics: 73% undervalued \"The large, global demand for obesity treatments is aligning with VK2735’s late-stage development in two formulations, which positions Viking Therapeutics to address a wide range of patient preferences…\" Read one of the top narratives on Viking Therapeutics Do you think there's more to the story for Viking Therapeutics? Head over to our Community to see what others are saying! The Bottom Line Viking Therapeutics now screens as overvalued on market multiples, with a price that sits well above both sector and close peer benchmarks on P/B. That does not rule out further upside. However, it does mean a lot of success with its diabetes and metabolic pipeline already sits in the valuation. The real divide between bulls and bears is whether future trial results and eventual commercial execution will be strong enough to keep investors comfortable paying this premium multiple.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655081536","isCrawlerRequest":true}